Etcamah: EU Breast Cancer Breakthrough
AstraZeneca Secures EU Approval for Etcamah, Expanding First-Line Breast Cancer Treatment Options
Anonymous
Key Points
1
SER Serena-6 trial uses a ctDNA-guided design that enables early detection of ESR1 mutations and timely switching to Etcamah-plus-CDK4/6 therapy, which may enhance frontline management for ESR1-mutant ER-positive/HER2-negative breast cancer.
2
European Commission approval followed a positive opinion from the CHMP (Committee for Medicinal Products for Human Use), signaling regulatory support prior to EC clearance.
3
Etcamah in Europe is approved in combination with all widely used CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) for ESR1-mutant ER-positive/HER2-negative advanced breast cancer in the first-line setting.
4
AstraZeneca characterized Etcamah as part of a broader growth plan, noting it as the 11th new medicine of the 20 expected to launch by 2030, underscoring its expanding oncology and precision-medicine portfolio.
5
U.S. regulatory review of Etcamah remains ongoing, with the FDA extending its decision deadline to evaluate updated SER Serena-6 results.
The European Commission has approved Etcamah (camizestrant) as a first-line treatment for a specific type of advanced breast cancer, AstraZeneca announced. The drug works in combination with CDK4/6 inhibitors — a widely used class of cancer medicines — for patients whose tumors carry ESR1 mutations and test positive for hormone receptors but negative for HER2. Nasdaq reports it is the first next-generation oral SERD cleared in this frontline setting in the EU.
The approval is based on the SERENA-6 Phase III trial, which showed a 56% reduction in the risk of disease progression or death. Patients on Etcamah lived a median 16.0 months without their cancer getting worse, compared to just 9.2 months on standard therapy, according to MarketScreener.
SERENA-6 Trial Used DNA Tests to Catch Mutations Early
The SERENA-6 trial used a cutting-edge design built around circulating tumor DNA, or ctDNA — tiny fragments of cancer DNA found in the blood. Doctors used ctDNA tests to spot ESR1 mutations early, before patients' cancer visibly worsened. When a mutation appeared, patients switched to Etcamah-based therapy right away. This approach allowed treatment to adapt in real time, MarketScreener reported.
ESR1 mutations are a key reason why hormone receptor–positive breast cancers stop responding to standard treatments over time. By catching these mutations early and switching therapy fast, the trial design aims to stay one step ahead of the cancer's resistance. The results suggest this strategy works: a 16.0-month median progression-free survival is a meaningful jump over the 9.2-month benchmark.
EU Regulator Cleared All Three CDK4/6 Inhibitor Combinations
The European Commission acted on a positive opinion from the CHMP — the EU's drug review committee — before granting full approval, LSE reported. The green light covers Etcamah used alongside all three major CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. These drugs are already standard care for hormone receptor–positive breast cancer, meaning Etcamah can slot into existing treatment plans.
Etcamah had already been approved in Japan, the UAE, and Saudi Arabia before this EU decision. The combination of multiple country approvals in a short window signals strong regulatory confidence in the drug's data. AstraZeneca is now pursuing approvals in additional markets, with the EU clearance adding significant reach across a large patient population.
FDA Decision Still Pending After Deadline Extension
The U.S. Food and Drug Administration has not yet approved Etcamah. The FDA extended its review deadline to allow time to evaluate updated SERENA-6 results, Nasdaq reported. The extension is not unusual — it often happens when a company submits new data during a review. AstraZeneca has not said when a U.S. decision is expected.
Etcamah Is Drug 11 of 20 AstraZeneca Plans by 2030
AstraZeneca called Etcamah the 11th new medicine in its plan to launch 20 drugs by 2030. The company is betting heavily on precision oncology — treatments that target specific genetic traits in tumors. Etcamah fits that strategy: it only applies to patients with ESR1 mutations, a defined and testable group, according to Nasdaq.
Hormone receptor–positive, HER2-negative breast cancer is the most common type of breast cancer globally. Endocrine resistance — when tumors stop responding to hormone-blocking drugs — is a major challenge in treating it. AstraZeneca says Etcamah is designed to directly address that resistance, offering a new option in a setting where treatment choices have historically been limited, MarketScreener noted.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
35
Reach
48
Topics
A
AnonymousAuthor